Vanda Pharmaceuticals Inc.
NASDAQ: VNDA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mihael H. Polymeropoulos
- Employees
- 368
- Headquarters
- Washington, United States
- IPO year
- 2006
- Market cap
- $354.8M
- Website
- https://www.vandapharma.com
Loading VNDA…
Loading profile data…Frequently asked questions about VNDA
What does Vanda Pharmaceuticals Inc. (VNDA) do?
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Va...
Where does VNDA trade?
Vanda Pharmaceuticals Inc. (VNDA) trades on the NASDAQ Global Market.
What sector is VNDA in?
Vanda Pharmaceuticals Inc. (VNDA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Vanda Pharmaceuticals Inc.?
Mihael H. Polymeropoulos is the chief executive officer of Vanda Pharmaceuticals Inc. (VNDA).
Where is Vanda Pharmaceuticals Inc. headquartered?
Vanda Pharmaceuticals Inc. is headquartered in United States.
Does VNDA pay a dividend?
Vanda Pharmaceuticals Inc. (VNDA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VNDA go public?
Vanda Pharmaceuticals Inc. (VNDA) completed its initial public offering in 2006.